Drug response prediction (DRP) is a longstanding challenge in modern oncology that underpins personalized treatment. Early DRP methods, trained on label-rich cell line samples, suffer from performance degradation when applied to label-scarce patient samples due to the distribution shift. Recently, a few transfer learning efforts have addressed this issue by aligning cell line (source domain) and patient (target domain) data via unsupervised domain adaptation (UDA). However, these efforts often treat each drug's response prediction as an isolated task, requiring model retraining when the drug changes; and focus only on aligning data distributions as a whole, neglecting the category (e.g., different cancers or tissues) confusion problem. To address these limitations, we propose a knowledge-guided domain adaptation model to transfer the DRP from cell lines to patients, named TransDRP. Specifically, TransDRP operates in two phases: pre-training and adaptation. In the first phase, we pre-train a multi-label graph neural network using molecular knowledge, to simultaneously predict responses for various drugs and capture their interdependencies. In the second phase, we implement a global-local domain adversarial strategy with clinical knowledge, to encourage representation alignment within same cancer categories and separation among different cancer categories across domains. Extensive experiments demonstrate that TransDRP outperforms state-of-the-art UDA methods in both transfer efficiency and precision for the patient DRP.

Using computational methods to personalize drug response prediction holds great promise to improve cancer therapy. Most existing methods use either biochemical information or response-related networks to predict drug response, nevertheless, the information they considered is not comprehensive. In this study, we present a novel end-to-end deep learning-based method Graph Neural Network with multi-task learning for Drug Response Prediction (GNNDRP). It leverages biochemical features as well as the hidden features from the heterogeneous network which incorporates the known drug-cell line responses, drug similarities, and cell line similarities, to complete the drug response prediction task. Moreover, GNNDRP designs a self-supervised task to enhance the representation capacity from the response network and further improve the model prediction performance. Extensive experiments show that GNNDRP outperforms existing state-of-the-art prediction methods under various experimental settings. The ablation analysis reveals that the biochemical characteristics, response-related network, and our self-supervised strategy can boost the predictive power. Additionally, case studies further validate the effectiveness of GNNDRP in identifying novel drug-cell line responses.

Therapeutic peptides represent a unique class of pharmaceutical agents crucial for the treatment of human diseases. Recently, deep generative models have exhibited remarkable potential for generating therapeutic peptides, but they only utilize sequence or structure information alone, which hinders the performance in generation. In this study, we propose a Multi-Modal Contrastive Diffusion model (MMCD), fusing both sequence and structure modalities in a diffusion framework to co-generate novel peptide sequences and structures. Specifically, MMCD constructs the sequence-modal and structure-modal diffusion models, respectively, and devises a multi-modal contrastive learning strategy with inter-contrastive and intra-contrastive in each diffusion timestep, aiming to capture the consistency between two modalities and boost model performance. The inter-contrastive aligns sequences and structures of peptides by maximizing the agreement of their embeddings, while the intra-contrastive differentiates therapeutic and non-therapeutic peptides by maximizing the disagreement of their sequence/structure embeddings simultaneously. The extensive experiments demonstrate that MMCD performs better than other state-of-the-art deep generative methods in generating therapeutic peptides across various metrics, including antimicrobial/anticancer score, diversity, and peptide-docking.

Identifying links within biological networks is important in various biomedical applications. Recent studies have revealed that each node in a network may play a unique role in different links, but most link prediction methods overlook distinctive node roles, hindering the acquisition of effective link representations. Subgraph-based methods have been introduced as solutions but often ignore shared information among subgraphs. To address these limitations, we propose a Subgraph-aware Graph Kernel Neural Network (SubKNet) for link prediction in biological networks. Specifically, SubKNet extracts a subgraph for each node pair and feeds it into a graph kernel neural network, which decomposes each subgraph into a combination of trainable graph filters with diversity regularization for subgraph-aware representation learning. Additionally, node embeddings of the network are extracted as auxiliary information, aiding in distinguishing node pairs that share the same subgraph. Extensive experiments on five biological networks demonstrate that SubKNet outperforms baselines, including methods especially designed for biological networks and methods adapted to various networks. Further investigations confirm that employing graph filters to subgraphs helps to distinguish node roles in different subgraphs, and the inclusion of diversity regularization further enhances its capacity from diverse perspectives, generating effective link representations that contribute to more accurate link prediction.

Drug-drug interactions (DDIs) could lead to various unexpected adverse consequences, so-called DDI events. Predicting DDI events can reduce the potential risk of combinatorial therapy and improve the safety of medication use, and has attracted much attention in the deep learning community. Recently, graph neural network (GNN)-based models have aroused broad interest and achieved satisfactory results in the DDI event prediction. Most existing GNN-based models ignore either drug structural information or drug interactive information, but both aspects of information are important for DDI event prediction. Furthermore, accurately predicting rare DDI events is hindered by their inadequate labeled instances. In this paper, we propose a new method, Multi-Relational Contrastive learning Graph Neural Network, MRCGNN for brevity, to predict DDI events. Specifically, MRCGNN integrates the two aspects of information by deploying a GNN on the multi-relational DDI event graph attributed with the drug features extracted from drug molecular graphs. Moreover, we implement a multi-relational graph contrastive learning with a designed dual-view negative counterpart augmentation strategy, to capture implicit information about rare DDI events. Extensive experiments on two datasets show that MRCGNN outperforms the state-of-the-art methods. Besides, we observe that MRCGNN achieves satisfactory performance when predicting rare DDI events.

Identifying the potential associations among drugs, microbes and diseases is of great significance in exploring the pathogenesis and improving precision medicine. There are plenty of computational methods for pair-wise association prediction, such as drug-microbe and microbe-disease associations, but few methods focus on the higher-order triple-wise drug-microbe-disease (DMD) associations. Driven by the advancement of hypergraph neural networks (HGNNs), we expect them to fully capture high-order interaction patterns behind the hypergraph formulated by DMD associations and realize sound prediction performance. However, the confirmed DMD associations are insufficient due to the high cost of in vitro screening, which forms a sparse DMD hypergraph and thus brings in suboptimal generalization ability. To mitigate the limitation, we propose a Multi-view Contrastive Learning Hypergraph Neural Network, named MCHNN, for DMD association prediction. We design a novel multi-view contrastive learning on the DMD hypergraph as an auxiliary task, which guides the HGNN to learn more discriminative representations and enhances the generalization ability. Extensive computational experiments show that MCHNN achieves satisfactory performance in DMD association prediction and, more importantly, demonstrate the effectiveness of our devised multi-view contrastive learning on the sparse DMD hypergraph.

Accurate prediction of cancer drug response (CDR) is a longstanding challenge in modern oncology that underpins personalized treatment. Current computational methods implement CDR prediction by modeling responses between entire drugs and cell lines, without the consideration that response outcomes may primarily attribute to a few finer-level 'subcomponents', such as privileged substructures of the drug or gene signatures of the cancer cell, thus producing predictions that are hard to explain. Herein, we present SubCDR, a subcomponent-guided deep learning method for interpretable CDR prediction, to recognize the most relevant subcomponents driving response outcomes. Technically, SubCDR is built upon a line of deep neural networks that enables a set of functional subcomponents to be extracted from each drug and cell line profile, and breaks the CDR prediction down to identifying pairwise interactions between subcomponents. Such a subcomponent interaction form can offer a traceable path to explicitly indicate which subcomponents contribute more to the response outcome. We verify the superiority of SubCDR over state-of-the-art CDR prediction methods through extensive computational experiments on the GDSC dataset. Crucially, we found many predicted cases that demonstrate the strength of SubCDR in finding the key subcomponents driving responses and exploiting these subcomponents to discover new therapeutic drugs. These results suggest that SubCDR will be highly useful for biomedical researchers, particularly in anti-cancer drug design.

Exploring the transcriptional response after employing chemical compounds assists in treating gene-related diseases and understanding biological activity of compounds. Calculating the similarity of drug transcriptional response can help to discover novel compounds that have the similar biological activity to known drugs for treating the same disease. Considering the transcriptional profiles of compounds are limited and harder to get than the structure of compounds, it is worth modeling the structure-transcriptional response similarity relationship. In this paper, we propose a signed graph convolutional network (SGCN)-based method, namely SGCN-DTRS, to predict drug transcriptional response similarity, which is quantitatively measured by Connectivity Map (CMap) scores, from their structures. SGCNDTRS constructs a CMap signed network from compounds and their CMap scores in the training data, which takes compounds as nodes, molecular structural representations of compounds as the attributes of nodes, and similarity relations between compounds as edges. Then SGCN-DTRS learns the CMap compound embeddings to predict CMap scores of pairwise compounds. Extensive experiments verify the superiority of the proposed method against the compared state-of-the-art methods and reveal that the relational information of the CMap data, which is learned from CMap signed network, is important for the CMap score prediction. SGCN-DTRS can not only work for the compounds in the training set but also is applicable to unseen compounds.

Predicting the response of a cancer cell line to a therapeutic drug is an important topic in modern oncology that can help personalized treatment for cancers. Although numerous machine learning methods have been developed for cancer drug response (CDR) prediction, integrating diverse information about cancer cell lines, drugs and their known responses still remains a great challenge. In this paper, we propose a graph neural network method with contrastive learning for CDR prediction. GraphCDR constructs a graph neural network based on multi-omics profiles of cancer cell lines, the chemical structure of drugs and known cancer cell line-drug responses for CDR prediction, while a contrastive learning task is presented as a regularizer within a multi-task learning paradigm to enhance the generalization ability. In the computational experiments, GraphCDR outperforms state-of-the-art methods under different experimental configurations, and the ablation study reveals the key components of GraphCDR: biological features, known cancer cell line-drug responses and contrastive learning are important for the high-accuracy CDR prediction. The experimental analyses imply the predictive power of GraphCDR and its potential value in guiding anti-cancer drug selection.

MiRNAs are a class of small non-coding RNA molecules that play an important role in many biological processes, and determining miRNA-disease associations can benefit drug development and clinical diagnosis. Although great efforts have been made to develop miRNA-disease association prediction methods, few attention has been paid to in-depth classification of miRNA-disease associations, e.g. up/down-regulation of miRNAs in diseases. In this paper, we regard known miRNA-disease associations as a signed bipartite network, which has miRNA nodes, disease nodes and two types of edges representing up/down-regulation of miRNAs in diseases, and propose a signed graph neural network method (SGNNMD) for predicting deregulation types of miRNA-disease associations. SGNNMD extracts subgraphs around miRNA-disease pairs from the signed bipartite network and learns structural features of subgraphs via a labeling algorithm and a neural network, and then combines them with biological features (i.e. miRNA-miRNA functional similarity and disease-disease semantic similarity) to build the prediction model. In the computational experiments, SGNNMD achieves highly competitive performance when compared with several baselines, including the signed graph link prediction methods, multi-relation prediction methods and one existing deregulation type prediction method. Moreover, SGNNMD has good inductive capability and can generalize to miRNAs/diseases unseen during the training.

MOTIVATION: There are various interaction/association bipartite networks in biomolecular systems. Identifying unobserved links in biomedical bipartite networks helps to understand the underlying molecular mechanisms of human complex diseases and thus benefits the diagnosis and treatment of diseases. Although a great number of computational methods have been proposed to predict links in biomedical bipartite networks, most of them heavily depend on features and structures involving the bioentities in one specific bipartite network, which limits the generalization capacity of applying the models to other bipartite networks. Meanwhile, bioentities usually have multiple features, and how to leverage them has also been challenging. RESULTS: In this study, we propose a novel multi-view graph convolution network (MVGCN) framework for link prediction in biomedical bipartite networks. We first construct a multi-view heterogeneous network (MVHN) by combining the similarity networks with the biomedical bipartite network, and then perform a self-supervised learning strategy on the bipartite network to obtain node attributes as initial embeddings. Further, a neighborhood information aggregation (NIA) layer is designed for iteratively updating the embeddings of nodes by aggregating information from inter- and intra-domain neighbors in every view of the MVHN. Next, we combine embeddings of multiple NIA layers in each view, and integrate multiple views to obtain the final node embeddings, which are then fed into a discriminator to predict the existence of links. Extensive experiments show MVGCN performs better than or on par with baseline methods and has the generalization capacity on six benchmark datasets involving three typical tasks. AVAILABILITY AND IMPLEMENTATION: Source code and data can be downloaded from https://github.com/fuhaitao95/MVGCN. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.

MOTIVATION: Drug combinations have exhibited promise in treating cancers with less toxicity and fewer adverse reactions. However, in vitro screening of synergistic drug combinations is time-consuming and labor-intensive because of the combinatorial explosion. Although a number of computational methods have been developed for predicting synergistic drug combinations, the multi-way relations between drug combinations and cell lines existing in drug synergy data have not been well exploited. RESULTS: We propose a multi-way relation-enhanced hypergraph representation learning method to predict anti-cancer drug synergy, named HypergraphSynergy. HypergraphSynergy formulates synergistic drug combinations over cancer cell lines as a hypergraph, in which drugs and cell lines are represented by nodes and synergistic drug-drug-cell line triplets are represented by hyperedges, and leverages the biochemical features of drugs and cell lines as node attributes. Then, a hypergraph neural network is designed to learn the embeddings of drugs and cell lines from the hypergraph and predict drug synergy. Moreover, the auxiliary task of reconstructing the similarity networks of drugs and cell lines is considered to enhance the generalization ability of the model. In the computational experiments, HypergraphSynergy outperforms other state-of-the-art synergy prediction methods on two benchmark datasets for both classification and regression tasks and is applicable to unseen drug combinations or cell lines. The studies revealed that the hypergraph formulation allows us to capture and explain complex multi-way relations of drug combinations and cell lines, and also provides a flexible framework to make the best use of diverse information. AVAILABILITY AND IMPLEMENTATION: The source data and codes of HypergraphSynergy can be freely downloaded from https://github.com/liuxuan666/HypergraphSynergy. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.

Gene expression and immune status in human tissues are changed with aging. There is a need to develop a comprehensive platform to explore the dynamics of age-related gene expression and immune profiles across tissues in genome-wide studies. Here, we collected RNA-Seq datasets from GTEx project, containing 16 704 samples from 30 major tissues in six age groups ranging from 20 to 79 years old. Dynamic gene expression along with aging were depicted and gene set enrichment analysis was performed among those age groups. Genes from 34 known immune function categories and immune cell compositions were investigated and compared among different age groups. Finally, we integrated all the results and developed a platform named ADEIP (http://gb.whu.edu.cn/ADEIP or http://geneyun.net/ADEIP), integrating the age-dependent gene expression and immune profiles across tissues. To demonstrate the usage of ADEIP, we applied two datasets: severe acute respiratory syndrome coronavirus 2 and human mesenchymal stem cells-assoicated genes. We also included the expression and immune dynamics of these genes in the platform. Collectively, ADEIP is a powerful platform for studying age-related immune regulation in organogenesis and other infectious or genetic diseases.